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Abstract 
Background: Enhancing medication safety, strengthening compliance and mitigating side effects 
requires close monitoring.  A child, defined by Centers for Medicare and Medicaid Services, as 
being between the ages of 6 years and 12 years of ages, with Attention Deficit Hyperactivity 
Disorder (ADHD) must have an initial medication visit within 30 days of a first-time trial of 
ADHD medication.  Increasing staff awareness of organizational policy of expected timeframe for 
medication checks and annotating appointment slots as initial medication checks will decrease the 
number of days between the first-time trial of ADHD medication and a child’s medication 
assessment.  
Methods: The Model for Improvement and Plan, Do, Study, Act structure for quality improvement 
worked well for this project.  A 3-month retrospective chart review was completed, prior to the 
implementation of the intervention.  A total of 600 charts were reviewed for the start date of ADHD 
medication and date of initial medication assessment.  
Intervention: Administrative staff and APRNs were educated about CMS measures and 
organizational controlled medication policies.  Appointment slots were annotated as initial 
medication checks. Due to COVIS 19, the visit platform was changed from in person to telehealth.  
CMS measures, organizational policy and process changes were included in a weekly email to 
both administrative staff and APRNs.  
Results:  Follow up chart reviews (n=591) revealed the mean number of days between starting an 
ADHD medication to the initial medication assessment, in the 3 months after implementation, 
decreased from 43 days to 20 days, an overall reduction of 23 days or 73%, meeting both CMS 
measures and organizational policy.  
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Conclusion: Increased awareness, reinforcement, annotation of appointments and a change to 
telehealth platform successfully decreased the mean number of days between ADHD medication 
initiation and follow up medication evaluation.  Limitations include: the project taking place in the 
setting of an epidemic, an announcement that The ADHD Center would be closing and not having 
data to compare in person visits to telehealth visits.  
 Keywords:  ADHD, medication, initiation  
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Timely Follow Up Care After Initiation of ADHD Medication in Children: 
A Quality Improvement Project 
Attention Deficit/Hyperactivity Disorder (ADHD) is a chronic mental health disorder 
characterized by deficits in attention and focus, poor impulse control, and high activity levels 
that impair daily functioning.  The diagnosis of ADHD is based on the criteria outlined by The 
Diagnostic and Statistical Manual of Mental Disorders (DSM).  ADHD is one of the most 
prevalent mental health disorders in children.  To qualify for a diagnosis of ADHD, symptoms 
must result in impairment of social, academic, or other functioning that cannot be explained or 
attributed to another physical condition, mental health condition, or social situation (Brown et 
al., 2017).  11% of American children have been diagnosed with ADHD (National Committee 
for Quality Assurance [NCQA], 2020).  In 2007, 6.9% of the children in Connecticut had been 
diagnosed with ADHD as compared to 9.5% nationwide.  In 2011 these number grew to 8.7% in 
Connecticut and 11% nationwide.  In 2011, of the children diagnosed with ADHD, 5.1% in 
Connecticut were taking medication and 6.1% nationwide were taking medication for ADHD 
(Connecticut, 2020) (See Appendix A).  
Problem Description 
Medication is the single most common treatment for ADHD in children ages 6 to 12 
(Mayo Clinic, 2019).  Children with ADHD often experience impaired academic, social, and 
family difficulties, given this, medication discontinuity is a major public health concern 
(Brinkman et al., 2018).  The most common reasons for discontinuation of ADHD medication, as 
reported by the APRNs at The ADHD Center, are loss of appetite, difficulty sleeping, GI distress 
and anger / irritability. Brinkman et al indicate that medication adherence is poor in children, as 
they or their parents, will often stop and restart medication during the first year of treatment.  
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This was a phenomenon often seen at The ADHD Center.  Patients often come in with their 
parents for their follow up medication check reporting that the parent or the child stopped taking 
the prescribed medication due to side effects, long before coming to the appointment.  The 
medication is stopped without a call to the provider or scheduling a sooner appointment.  
CMS contracted with NCQA to develop a strategy to evaluate the quality of care for this 
population.  NCQA established Health Effectiveness Data and Information Set (HEDIS) 
measures used to identify opportunities for improvement, monitor the success of quality 
improvement initiatives, track improvement, and provide a set of measurement standards that 
allow comparison with other plans.  A lack of adherence to these CMS standards was the 
impetus for this project.  HEDIS and Centers for Medicare and Medicaid Services (CMS) 
recommend the quality metric be one follow-up appointment with a medical provider within 30 
days of initiating treatment with ADHD medication (AJMC, 2017).  American Academy of 
Family Physicians (AAFP) and NCQA specify that the follow up medication visit be with a 
physician or a prescribing provider.  This CMS measure was reviewed and endorsed on June 6, 
2020.  The goal being close monitoring of children who have newly started an ADHD 
medication for effectiveness, side effects, and adherence (NCQA, 2020).  
Treating ADHD can be costly when medical expenses, price of medication, costs to the 
educational system, and lost wages for caregivers of children with ADHD are considered.  In 
2011, the annual estimated cost of ADHD to society was approximately $14,500 per child, $42.5 
billion total.  This includes mental health utilization, medication, educational costs and work-loss 
related costs (Robb et al., 2011).  The aim of this project was to decrease the number of days 
between initiation of ADHD medication and the following medication assessment for children at 
The ADHD Center in order to be consistent with the HEDIS recommendations and less frequent 
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stoppage of medication.  Appointments with Advanced Practice Registered Nurses (APRNs) at 
The ADHD Center were often booked up to two months in advance, leaving more than a 30-day 
delay for an assessment visit in the patient who had just started ADHD medication.  The ADHD 
Center often had a waiting list. Waiting lists are a common barrier to treatment (Wright, et al., 
2015).  Prior to this improvement project, administrative staff were not aware of the 
recommendations and guidelines.  The global aim of this quality improvement project was to 
align The ADHD Center process with CMS measures and organizational policy.  Following 
CMS measures and organizational policy protects the safety of the patients by decreasing the 
risks of medication nonadherence.  Discontinuation of ADHD medication may result in: social 
and academic difficulties, substance abuse, delinquency, accidental injury, and poor economic, 
social, and emotional well-being and improves the quality of care and quality of life for pediatric 
ADHD patients by having patients follow up within 30 days of starting ADHD medication 
(Sikirica, et al., 2014).  
Available Knowledge 
ADHD is the most common behavioral disorder in childhood (Office of the National 
Coordinator for Health Information Technology/Centers for Medicare & Medicaid Services 
[psychiatry.org], n.d.).  The prevalence continues to rise year over year.  The goal of ADHD 
treatment is to improve symptoms and optimize functioning for children in both home and school 
settings.  CMS and National Committee for Quality Assurance (NCQA) standards state that there 
be a follow up visit with a provider within 30 days after a first-time trial of ADHD medication. 
Blood pressure (bp), pulse, weight, height, side effects, the severity of ADHD symptoms and the 
effectiveness of medication should be assessed at this visit.  The goal was to align The ADHD 
Center process with CMS measures and organizational policy the purpose of which is to improve 
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symptomology and adherence to prescribed medication, alleviate side effects and decrease the 
rate of discontinuation.  The way to achieve this was by changing the process at The ADHD 
Center to match CMS measures and organizational policy, that children be seen within 30 days 
of initiation of ADHD medication.  
According to NCQA, when ADHD medication is managed correctly it has the potential 
to control the symptoms of inattention, hyperactivity, and impulsivity.  For ADHD medication to 
be managed appropriately, children should be closely monitored by the prescribing provider. 
Pharmacological treatment of ADHD is associated with improved academic achievement in 
elementary school, improved health and quality of life, and is central to the physical, emotional 
and psychological wellbeing of children with ADHD (Shier et al., 2013; Brown, 2018).  
Adherence to CMS measures and organizational policy were the motivation for this 
improvement project, but the value goes much deeper.  When ADHD symptoms are treated 
effectively children and adolescents can achieve full potential in all areas of life:  social, 
academic, and family functioning (Brown et al., 2017, p. 45).  Wolraich, et al. (2019) indicate 
that ADHD medication is often discontinued, placing children at higher risk for significant 
problems.  Effective ADHD medication management mitigates the risk of discontinuing 
treatment.  ADHD medication, prescribed with close clinical supervision, in addition to school 
accommodations, and behavioral interventions improves the chances for children with ADHD to 
grow in to healthy and productive adults.  
Rationale  
 The Institute for Healthcare Improvement (IHI) Model for Improvement guided this 
process improvement project (Department of Health, 2011) (see Appendix B).  The model has 
two equally important parts.  The first asks three questions:  
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1. What are we trying to accomplish?  
2. How will we know whether a change is an improvement?  
3. What changes can we make that will result in an improvement? 
The second part of this model, Plan, Do, Study, Act (PDSA) cycle, tests and implements 
changes in work settings (health.ny.gov, 2011).  
The ADHD Center practice is to have all medication related visits completed by a 
physician or advanced practice clinician (APC).  The intervention involved an assessment of 
level of The ADHD Center staff knowledge of CMS measures and organizational policy, 
increasing awareness, and changing the scheduling process.  With increased awareness and 
knowledge, weekly reinforcement, and a change in scheduling process and platform, adherence 
to follow up medication recommendations improved.  
Plan, Do, Study, Act (PDSA) cycle  
Plan 
The plan phase of the PDSA cycle addresses the who? what? where? and when? of data 
collection.  The plan included a retrospective chart review, extracting data from the electronic 
health record (EHR) for first-time trials of ADHD medication and the length of time until the 
following medication check.  Data from two APRNs, APRN 1 and APRN 2 were utilized.  The 
dates used for retrospective extraction of data were November 2019, December 2019, and 
January 2020.   The dates were chosen to coordinate with the hire of the second (APRN 2), who 
started practicing at The ADHD Center in October of 2019 and ramped up to a full schedule by 
November 2019.   The dates of implementation of the plan were June, July and August of 2020.   
Using data collected from the same months for both APRNs allowed for greater parity.  
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Do  
Details of how the plan was carried out, observations documented, and data recorded 
were addressed in the “do” phase of the PDSA cycle.  A gap analysis was completed by direct 
observation of the current process. 
Patients scheduled for follow up medication checks more than 30 days after medication 
initiation was the existing process state.  The desired process state was that patients newly 
prescribed medication be scheduled within 30 days for a follow up medication check via 
telehealth platform. Herein laid the process gap (SHRM, 2018).  
A virtual meeting was held wherein the observations were shared, staff were asked about 
their existing knowledge of CMS measures and organizational policy and current process. 
Administrative staff were not aware of the gaps in the process.  Level of knowledge of CMS 
measures and organizational policy was ascertained via formative assessment (see Appendix C). 
Formative assessments offer qualitative feedback, assesses strengths and weaknesses, and offers 
a productive and intense educational experience (Abu-Zaid, 2013).  APRNs were not aware of 
CMS measures but were aware of organizational policy.  There was an obvious knowledge gap.  
The project leader read both the CMS measures and the organization’s controlled medication 
policy and explained the gap in the process and the intent to change the process.  Each staff 
member was given the opportunity to add their ideas for changing and improving the current 
process laying the groundwork for a new process.  
Designated slots were to be changed from a general 30-minute follow up visit to an initial 
medication check in the APRN schedule by administrative staff through the scheduling program. 
Initial medication assessments were to be annotated on the schedule as “initial med check”. 
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Weekly emails reviewing measures, policies, and interventions were sent to both administrative 
staff and APRN 1 and APRN 2. 
Study 
In the study phase of the PDSA cycle, data was analyzed, results compared to predictions 
and the findings summarized.  The following data were collected: start date of ADHD 
medication for APRN 1 and APRN 2, the date of the visit immediately following start of ADHD 
medication for APRN 1 and APRN 2, the total number of days in between starting medication 
and follow up.   
Using a quantitative design allowed for observations to be made about a subject that had 
previously been unexplored.  The hypothesis was that when staff have knowledge and 
understanding of standards and policies and a change made to the process, The ADHD Center 
performance would align with CMS measures and organizational policy and the number of days 
between starting ADHD medication and the follow up medication check would  decrease.  The 
null hypothesis is that the process change causes no change in the number of days between 
starting ADHD medication and the follow up medication check.  Paired t-tests were executed for 
APRN 1 and APRN 2.  The mean number was identified separately and then combined.  
Act 
The “act” phase dealt with changes made to the process.  Administrative staff annotated 
“initial med check” on the providers’ schedule.  Educational reinforcement emails were sent 
weekly by the project leader to administrative staff and APRN 1 and APRN 2 recapping CMS 
measures and organizational policy and the updated scheduling process for the intervention.  
Specific Aims  
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The specific aim of this project was to align The ADHD Center process with CMS 
measures and organizational policy related to children with ADHD by decreasing the number of 
days between a first-time trial of ADHD medication and the following medication check.  The 
CMS measure reads: 
Initiation Phase:  Assesses children between 6 and 12 years of age, who were diagnosed with 
ADHD, and had one follow-up visit with a practitioner with prescribing authority within 30 days 
of their first prescription of ADHD medication. 
(CMS, 2020)   
Methods 
Context 
The ADHD Center is in the Northeastern United States and is a specialty clinic within a 
larger healthcare organization.  The ADHD Center is the only mental health clinic within the 
larger organization. The larger organization is predominantly compromised of primary care, 
internal medicine, family practice, and pediatric practices.  The entire organization was acquired 
by a nationally recognized healthcare / insurance corporation in December of 2016.  The ADHD 
Center consisted of: 3 APRNS each of whom works four to five days per week; a developmental 
pediatrician, who served as medical director and works two days per week; a pediatrician who 
worked within the organization in a pediatric practice four days per week and one day per week 
at The ADHD Center and a psychiatrist who consulted at the center ½ day per week; two special 
education teachers; an office manager; and three support staff.  The ADHD Center would receive 
multiple requests daily for new evaluations.  The ADHD Center had an extensive waiting list.  
The services offered are in high demand.  What made The ADHD Center unique and separated it 
from other ADHD centers and ADHD providers was the evidence-based testing, individualized 
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treatment, interface with school and community-based therapists, responsivity of the staff, and 
providers specially trained in treating ADHD.  Patients would come to the center from all over 
the state and from several other states.  Specialized ADHD centers are uncommon in this area. 
The practice included both adult and pediatric patients, with a primary diagnosis of ADHD, as 
well as comorbid anxiety, depression and behavioral and educational concerns.  
The stakeholders in this quality improvement project are the patients and families, 
APRNs, The ADHD Center and the umbrella organization.  Approval to allocate designated 
initial medication visits was granted by the office manager and the business director.  Despite 
approval, the intervention was revised and reapproved with the start of the COVID-19 epidemic 
and visit platform shifting from in person visits to telehealth visits in April 2020.  Organizational 
policy states that patients started on an ADHD medication are to be seen within 30 days of 
initiation.  Once stable, follow up visits were scheduled at three-month intervals.  Scheduling an 
initial medication check after 30 days would add one additional visit in the first year for each 
child starting medication.  Patients who have not been stabilized on medication or who may be 
experiencing side effects, behavioral difficulties or school concerns require more frequent visits. 
Cost Analysis 
The ADHD Center had been accepting 24 new patients per month up until July.  About 
50% of all new patients were started on ADHD medication.  If follow up visits were scheduled 
within 30 days, this would have added an additional 12 initial medication visits per month.  
Adherence to CMS measures and organizational protocols would have generated 144 additional 
visits per 12-mont h period, at a rate of $181 per 30-minute medication check, totaling $26,064 
in additional revenue annually.  This would offset the cost of administrative time for regularly 
scheduled staff education.  
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Intervention 
The planned intervention was to designate two 30-minute visits per week per APRN 
annotated as “initial medication check” visits.  After the COVID-19 epidemic began, April 2020, 
The ADHD Center providers were mandated to work from home.  A telehealth platform was 
implemented, initially by phone and then by videoconferencing.  Processes were changed and 
schedules reconfigured.  Administrative staff were informed by the APRN that the next 
scheduled appointment was to be an initial medication check and annotated as such on the 
schedule.  Additionally, weekly email blasts were sent to administrative staff, APRN 1, and 
APRN 2 by the project leader, recapping organizational policy and updated processes.  
A retrospective audit of the EHR included all patient charts for APRN 1 and APRN 2 for 
the designated time periods.  The number of days between the first-time trial of an ADHD 
medication and the initial medication check for ADHD patients were extracted.  The following 
were the criteria for inclusion: subjects had to be a patient of The ADHD Center, ages 6 years 
old up to 12 years old, naïve to ADHD medication, and starting either a stimulant or non-
stimulant ADHD medication.  Exclusion criteria included: patients younger than 6 years old and 
older than 12 years, patients switching or restarting ADHD medication and patients starting 
medication for diagnoses other than ADHD. 
Study of the Intervention 
 The interventions included assessing staffs’ level of awareness of the organization’s 
medication policies and The ADHD Center process for initiating medication and scheduling the 
follow up visit.  Administrative staff were not aware of organizational policy.  APRNs were 
aware of medication policies but could not identity how or even if this was being monitored.  
Certain team members have access to important information that others do not.  This information 
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is of little value if it is not communicated to the entire team  (Haas & Mortensen, 2016).  CMS 
measures and organizational policies were read to both administrative staff and APRNs.  Level 
of understanding was evaluated by allowing time for questions, having staff repeat back 
information, and having administrative staff and APRNs demonstrate a mock trial run of the new 
process.  Weekly email reminders were sent by the project leader.  Application of the process 
was apparent by viewing the phrase “initial medication check” on the schedule.  
Measures 
The planned process change was to align The ADHD Center process with CMS quality 
metrics and organizational policy by reducing the number of days between initiation of ADHD 
medication and the following medication check.  The measures examined included the mean 
number of days between initiation of medication and the follow up medication assessment. The 
impact of the intervention would be the alignment of The ADHD Center process with the core 
measure set forth by CMS and organizational policy.  
Analysis 
Using a quantitative design and paired t-test allowed for an observation to be made about 
a subject that had been unexplored.  The original hypothesis is that staff education combined 
with annotations made to appointments will decrease the number of days between ADHD 
medication initiation and the follow up medication visit  
Ethical Considerations 
Potential ethical issues were considered.  Children with ADHD are considered a 
vulnerable population.  The children were not the subject of the project.  The focus of this quality 
improvement project was The ADHD Center process.  This improvement project meets the 
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criteria for quality improvement and therefore did not need human subjects’ approval as no 
identifying information or protected health information (PHI) was collected.  
 
Results 
Over the course of this project, 600 pre-intervention patient encounter records were 
reviewed for the months of November 2019, December 2019, and January 2020 and 591 post-
intervention patient encounter records were reviewed for the months of June 2020, July 2020 and 
August 2020 (see Appendix D).  
Figure 1 
Mean Number of Days  
 
The number of days between initiation of ADHD medication and the ensuing medication 
assessment visit pre-intervention were tracked for the same time period, November 2019, 
December 2019, and January 2020.  Figure 1 shows that the mean number of days for APRN 1 
was 52 days and for APRN 2 was 33 days.  The average was then taken from APRN 1 and 
APRN 2 combined, 43 days.  This was an average of 12 days longer than either CMS measures 








Mean Number of Days Pre-
intervention
Mean Number of Days Post-
intervention
APRN 1 APRN 2
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The two-tailed P value equals 0.0284.   This difference is considered to be statistically 
significant.  The mean of Group APRN 1 minus Group APRN 2 equals 16.69 with a 95% 
confidence interval.  
Table 1 
Paired T-test Values Pre-intervention 
Group APRN 1 APRN 2 
Mean 52.23 35.54 
SD 19.80 14.17 
SEM 5.49 3.93 
N 13 13 
 
The number of days between initiation of ADHD medication and initial medication 
evaluation were tracked again, post intervention for the time period of June 2020, July 2020, and 
August 2020.  The mean number of days for APRN 1 was 11 (N=1) and for APRN 2 was 29 
days (N=4).  The average was taken from APRN 1 and APRN 2 combined totaling 20 days.  The 
number of days was reduced by 23 days or 73%, meeting both CMS measures and organizational 
policy (see Appendix D).  
Missing Data 
There was not enough data for a paired t-test post-intervention.  A retrospective chart 
review totaled N=1 for APRN 1. A t-test cannot be performed when there is only one value.  The 
lack of data is attributable to the gradual winding down of patient care in preparation for the 
closing of the center.  
Discussion 
Summary 
The framework of the Model for Improvement for a rapid cycle change in process using a 
single PDSA cycle worked well for guiding this process.  Repeated PDSA cycles are needed to 
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make refinements and modifications and build knowledge.  Future PDSA cycles on a larger scale 
would likely lead to continued refinement and standardization of the process. The COVID-19 
epidemic forced staff to work from home, leading to a change in visit platform from in-person to 
telehealth. This changed the workflow and the process for scheduling appointments. A 
comparison of the pre and post COVID-19 process for scheduling visits would indicate whether 
the improvement in timely follow up care was related to the change in visit platform or to raising 
awareness of policies. The telehealth platform had never been used before at The ADHD Center.  
After the initial adjustment period, scheduled visits continued virtually.  Parents were pleased 
with this platform, cutting down on travel time and expense and wait time.  Parents were better 
able to fit a telehealth visit into their own and their child’s schedule interfering less in after 
school activities and missing less school time for appointments.  Brinkman states that one of the 
main reasons that children stop taking ADHD medication are “logistical barriers” of getting and 
taking medication (Brinkman et al., 2018).  APRN 1 and APRN 2 saw improved adherence to 
scheduled visits allowing for closer medication monitoring.  
By raising the level of awareness of staff, providing weekly recap emails, and annotating 
schedules there was a 73% decrease in the number of days between medication initiation and the 
follow up medication visit.  Follow up medication visits after initiation of medication were made 
within the 30-day window more often with the effects lasting the duration of the intervention 
period.  The process for scheduling follow up visits after initiation of ADHD medication aligned 
with CMS measures and organizational policy once the intervention was understood and 
implemented.  Staff awareness of measures and policies and the planned intervention lead to 
improved compliance.  Administrative staff and APRNs were eager to change the process once 
they were aware and understood the need and the potential positive outcomes for the patients.  
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When a team has direction and a common goal its’ members feel energized and engaged.  Shared 
knowledge increases efficiency (Haas & Mortensen, 2016).  
Limitations 
Fewer patients started ADHD medication than anticipated during the study period.  
Patients often sought out The ADHD Center for a second opinion after unsuccessful attempts at 
symptom treatment, wanting specialized care, or requiring help with accommodations and 
advocacy at school.  Patients that were new to The ADHD Center were not necessarily new to 
the ADHD diagnosis.  Hamed (2015) attributes this to “limited reimbursement for specialist 
evaluation or mental health care is a factor in diagnosis of ADHD, particularly for complex 
presentations that may require more clinician time”.   
There were several limiting factors over the course of this project.  The number of 
subjects was limited by CMS’s definition of a child as being between the ages of 6 and 12. 
Extending the time of both pre- and post-interventions would have yielded more robust data.  
The COVID-19 epidemic forced staff to work from home, leading to a change in visit platform 
from in-person to telehealth, changing the workflow and the process for scheduling 
appointments.  
Implementation of a meaningful performance improvement project includes the 
following recommendations: collection of data over a longer period of time, examining a clinic 
that has a large number of pediatric ADHD patients, when possible avoiding the start of a quality 
improvement project during an epidemic and replication in a clinic that is not closing.  Future 
PDSA cycles should focus on advancing the use of the telehealth platform.  
Conclusion 
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An unexpected opportunity arose out of this process improvement project.  It gave 
providers the chance to compare in person visits to telehealth visits for children with ADHD. 
Precautions related to the COVID-19 epidemic will likely be in place for the long term.  CMS 
standards and organizational policies will need to adapt to meet the challenge that COVID-19 
has presented.  The ADHD specialty lends itself well to the telehealth platform.  Future 
performance improvement projects will need to focus on the addition of the physical exam 
component of an ADHD medication visit, including height, weight, blood pressure and pulse. 
This is an integral part of an ADHD medication assessment and was not monitored as closely at 
the onset of the epidemic.  Sustainability of ADHD visits will depend on the ability to perform 
cardiovascular monitoring.  Existing and new capabilities available on smartphones make home 
monitoring an option.  New technology, transdermal optical imaging, uses a smartphone camera 
to capture images of imperceptible facial blood flow and uses machine learning to determine 
blood pressure from these images (McGrath, 2020).  
The ability of specialty care practices to provide quality clinical care for patients depends 
on the ability to understand the need for continuous quality monitoring and process 
improvement.  CMS standards and organizational policies are in place to ensure safe medication 
practices.  Safe prescribing practices, availability of a telehealth platform and close monitoring 
improve the level of adherence to taking medication as prescribed and attending scheduled 
appointment.    
Use of the telehealth platform has lent itself to ongoing monitoring in pediatric patients. 
The ADHD Center APRNs report that ADHD treatment performed in the telemedicine platform 
was equally as effective as in person services.  In addition, states have imposed requirements for 
parity in reimbursement for telemedicine.  The pediatric population is especially vulnerable, and 
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the benefits of appropriate ADHD treatment and safe ADHD medication prescribing practices 
reach into adulthood.  Staff awareness, process change and telehealth show promise for 
sustainability in pediatric ADHD treatment.  With Medicaid reimbursing for telehealth visits at 
the same rate as in person visits and the scarcity of ADHD treatment in this area, the telehealth 
platform has advantages for this specialty practice.    
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Appendix D 
Chart Review Raw Data 
Pre-intervention Total Patient Encounters 
Date APRN 1 APRN 2 
Total # of 
encounters 
November 2019 106 72 178 
December 2019 74 89 163 
January 2020 149 110 259 
Total # of 
encounters 
  600 
 
Post-intervention Total Patient Encounters 
Date APRN 1 APRN 2  
Total # of 
Encounters 
June 2020 104 117 221 
July 2020 89 99 188 
August 2020 79 103 182 
Total # of 
encounters  
272 319 591 
 
Data tracking pre-intervention 
APRN 1 Date of medication 
initiation 
Date of follow up # of days between 
initiation and follow up 
 1/10/2020 03/05/2020 55 
 11/22/2019 12/20/19 28 
 1/9/20 3/6/20 57 
 1/9/20 3/12/20 63 
 11/15/19 11/21/19 6 
 12/6/19 1/24/20 49 
 1/10/20 2/26/20 46 
 1/8/20 3/4/20 56 
 1/8/20 3/11/20 63 
 1/9/20 3/12/20 63 
 1/10/20 3/5/20 55 
 1/10/20 2/26/20 47 
 1/15/20 4/15/20 91 
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Data tracking pre-intervention 
APRN 2 Date of medication 
initiation 
Date of follow up # of days between 
initiation and follow up 
 11/4/19 12/9/19 35 
 11/4/19 12/5/19 31 
 11/7/19 12/19/19 42 
 12/4/19 1/9/19 36 
 11/16/19 12/16/19 30 
 12/12/19 01/14/20 33 
 12/19/19 01/22/20 34 
 12/4/19 1/9/20 36 
 12/24/19 1/13/20 20 
 12/30/19 3/3/20 63 
 1/15/20 1/27/20 12 
 1/3/20 3/5/20 62 
 1/28/20 2/25/20 28 
 
Data Tracking Post-intervention 
APRN 1  Date of medication 
initiation 
Date of follow up  # of days between 
initiation and follow up 
 6/19/20 6/30/20 11 
 
Data Tracking Post-intervention 
APRN 2 Date of medication 
initiation 
Date of follow up  # of days between 
initiation and follow up 
 6/17/20 07/13/20 26 
 7/6/20 08/03/20 28 
 6/26/20 7/27/20 31 
 6/29/20 7/31/20 32 
 
 
